Tan Kevin's Insider Trades & SAST Disclosures
Tan Kevin's most recent trade in Adeia Inc was a trade of 79,130 Common Stock done . Disclosure was reported to the exchange on March 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Tan Kevin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 79,130 | 318,678 (0%) | 0% | 0 | Common Stock | |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.72 per share. | 01 Mar 2025 | 25,583 | 239,548 (0%) | 0% | 15.7 | 402,165 | Common Stock |
| Aurinia Pharmaceuticals Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 7.92 per share. | 28 Feb 2025 | 500,000 | 9,929,500 (11%) | 0% | 7.9 | 3,960,000 | Common Shares |
| Aurinia Pharmaceuticals Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 7.85 per share. | 28 Feb 2025 | 399,280 | 8,828,780 (10%) | 0% | 7.9 | 3,134,348 | Common Shares |
| Aurinia Pharmaceuticals Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 8.02 per share. | 28 Feb 2025 | 351,962 | 9,281,462 (10%) | 0% | 8.0 | 2,822,735 | Common Shares |
| Aurinia Pharmaceuticals Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 8.00 per share. | 28 Feb 2025 | 148,038 | 9,429,500 (11%) | 0% | 8 | 1,184,304 | Common Shares |
| Aurinia Pharmaceuticals Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 7.97 per share. | 28 Feb 2025 | 100,720 | 8,929,500 (10%) | 0% | 8.0 | 802,738 | Common Shares |
| Aurinia Pharmaceuticals Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 8.09 per share. | 28 Feb 2025 | 100,000 | 10,029,500 (11%) | 0% | 8.1 | 809,000 | Common Shares |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 10,625 | 35,414 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 10,625 | 31,875 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 3.96 per share. | 13 Feb 2025 | 3,164 | 32,250 (0%) | 0% | 4.0 | 12,529 | Common Stock |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 132,300 | 132,300 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2025 | 11,250 | 28,862 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2025 | 11,250 | 22,500 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 3.89 per share. | 09 Jan 2025 | 4,073 | 24,789 (0%) | 0% | 3.9 | 15,849 | Common Stock |
| Aurinia Pharmaceuticals Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 9.09 per share. | 05 Dec 2024 | 500,000 | 8,429,500 (9%) | 0% | 9.1 | 4,545,000 | Common Shares |
| Aurinia Pharmaceuticals Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 9.01 per share. | 05 Dec 2024 | 400,000 | 7,929,500 (9%) | 0% | 9.0 | 3,604,000 | Common Shares |
| Aurinia Pharmaceuticals Inc | Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 8.91 per share. | 05 Dec 2024 | 300,000 | 7,529,500 (8%) | 0% | 8.9 | 2,673,000 | Common Shares |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.44 per share. | 19 Oct 2024 | 8,101 | 264,890 (0%) | 0% | 12.4 | 100,776 | Common Stock |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.60 per share. | 01 Sep 2024 | 4,366 | 272,991 (0%) | 0% | 12.6 | 55,012 | Common Stock |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 80,720 | 277,106 (0%) | 0% | 0 | Common Stock | |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.53 per share. | 01 Mar 2024 | 15,606 | 196,386 (0%) | 0% | 11.5 | 179,937 | Common Stock |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 85,000 | 85,000 | - | - | Employee Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 42,500 | 42,500 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Tan Kevin | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2024 | 11,250 | 33,750 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2024 | 11,250 | 13,243 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 8.20 per share. | 09 Jan 2024 | 3,935 | 9,308 (0%) | 0% | 8.2 | 32,267 | Common Stock |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.54 per share. | 20 Jul 2023 | 10,885 | 222,641 (0%) | 0% | 11.5 | 125,613 | Common Stock |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.01 per share. | 01 Jul 2023 | 793 | 233,526 (0%) | 0% | 11.0 | 8,731 | Common Stock |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 8.34 per share. | 31 May 2023 | 699 | 234,319 | - | 8.3 | 5,830 | Kevin Tanji |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 69,644 | 240,374 (0%) | 0% | 0 | Common Stock | |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.85 per share. | 01 Mar 2023 | 6,754 | 233,620 (0%) | 0% | 9.9 | 66,527 | Common Stock |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 32,220 | 170,730 (0%) | 0% | 0 | Common Stock | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2023 | 90,000 | 90,000 | - | - | Employee Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Kevin Tan | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2023 | 45,000 | 45,000 | - | - | Restricted Stock Units | |
| Adeia Inc | Kevin Tanji | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Oct 2022 | 63,937 | 137,946 (0%) | 0% | 0 | Common Stock | |
| Selecta Biosciences Inc | Kevin Tan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 340,000 | 340,000 | - | - | Employee Stock Option (right to buy) | |
| Selecta Biosciences Inc | Kevin Tan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 72,000 | 77,000 (0%) | 0% | 0 | Common Stock | |
| Selecta Biosciences Inc | Kevin Tan | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.03 per share. | 02 Dec 2021 | 5,000 | 5,000 (0%) | 0% | 3.0 | 15,127 | Common Stock |
| Selecta Biosciences Inc | Kevin Tan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Sep 2021 | 750,000 | 750,000 | - | - | Employee Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges